Targeting Molecular and Cellular Mechanisms in Tuberculosis
- Publisher:
- Springer
- Publication Type:
- Chapter
- Citation:
- Targeting Cellular Signalling Pathways in Lung Diseases, 2021, pp. 337-353
- Issue Date:
- 2021-07-03
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
| 978-981-33-6827-9_14.pdf | Published version | 633.47 kB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
The major global problems are the prevalence rate of Mycobacterium tuberculosis (Mtb) and processes of resistance against continuing therapy. The shortage of possible drug candidates and consumer recognition along with unhygienic procedures are the key explanations for MDR, TDR and XDR Mtb strains in rapid emergence. Mtb’s powerful molecular structure and drug resistance pathways, demands expertise to develop new anti-tuberculosis therapies. Eventually, the synthesis of modern genomic knowledge of drug resistance mechanisms in Mtb will offer a new path for combinatorial drug development and provide considerable support for highly successful anti-tubercular drugs.
After a time of relative lack of interest in cell envelope targeting inhibitors, the immediate necessity of new therapeutic approaches has motivated renewed work towards a deeper understanding of the cell envelope, its biogenesis and function during Mtb’s stages of proliferation, survival and reactivation. As a result, new appealing goals for drugs were identified and followed, with varying effects, in the form of target-based scanning and other target-based strategies. The challenge of detecting compounds whose inhibitory action against filtered targets translated into entire Mtb cell activity prompted several field investigators to go back to cell-based screens. This strategy leads to several new groups of inhibitors being identified, and some of those are now in preclinical research.
Please use this identifier to cite or link to this item: